Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Eur J Immunol. 2015 Dec 14;46(1):230–241. doi: 10.1002/eji.201545708

Figure 2. Changes in CD4+ and CD8+ T cell subsets in patients with T1D following treated with teplizumab.

Figure 2

(A) CD4+ and CD8+ CM and EM (percent of total) T cells in responders and non-responders in the first year after treatment in AbATE. The data shown represent the geometric mean±SEM from the repeated measures mixed model corrected for the baseline values. (*p<0.05, **p<0.01). (B) The changes in the CD8CM T cells were due to an increase in the absolute number of the cells in the responders in the AbATE trial (* p<0.05, **p<0.01). (C) In the Delay trial there was also a significant increase in the proportion of CD8CM T cells at month 2 (*p<0.05), corrected for the baseline values. There were not significant differences in the proportion of CD8EM T cells.